601 related articles for article (PubMed ID: 25450364)
1. Effect of 5-aminolevulinic acid on erythropoiesis: a preclinical in vitro characterization for the treatment of congenital sideroblastic anemia.
Fujiwara T; Okamoto K; Niikuni R; Takahashi K; Okitsu Y; Fukuhara N; Onishi Y; Ishizawa K; Ichinohasama R; Nakamura Y; Nakajima M; Tanaka T; Harigae H
Biochem Biophys Res Commun; 2014 Nov; 454(1):102-8. PubMed ID: 25450364
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathophysiology and genetic mutations in congenital sideroblastic anemia.
Fujiwara T; Harigae H
Free Radic Biol Med; 2019 Mar; 133():179-185. PubMed ID: 30098397
[TBL] [Abstract][Full Text] [Related]
3. Generation and Molecular Characterization of Human Ring Sideroblasts: a Key Role of Ferrous Iron in Terminal Erythroid Differentiation and Ring Sideroblast Formation.
Saito K; Fujiwara T; Hatta S; Morita M; Ono K; Suzuki C; Fukuhara N; Onishi Y; Nakamura Y; Kawamata S; Shimizu R; Yamamoto M; Harigae H
Mol Cell Biol; 2019 Apr; 39(7):. PubMed ID: 30670569
[TBL] [Abstract][Full Text] [Related]
4. Regulation and tissue-specific expression of δ-aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias.
Peoc'h K; Nicolas G; Schmitt C; Mirmiran A; Daher R; Lefebvre T; Gouya L; Karim Z; Puy H
Mol Genet Metab; 2019 Nov; 128(3):190-197. PubMed ID: 30737140
[TBL] [Abstract][Full Text] [Related]
5. Regulation of erythroid 5-aminolevulinate synthase expression during erythropoiesis.
Sadlon TJ; Dell'Oso T; Surinya KH; May BK
Int J Biochem Cell Biol; 1999 Oct; 31(10):1153-67. PubMed ID: 10582344
[TBL] [Abstract][Full Text] [Related]
6. GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in Human congenital sideroblastic anemia.
Daher R; Mansouri A; Martelli A; Bayart S; Manceau H; Callebaut I; Moulouel B; Gouya L; Puy H; Kannengiesser C; Karim Z
Mol Genet Metab; 2019 Nov; 128(3):342-351. PubMed ID: 30660387
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia.
Kaneko K; Furuyama K; Fujiwara T; Kobayashi R; Ishida H; Harigae H; Shibahara S
Haematologica; 2014 Feb; 99(2):252-61. PubMed ID: 23935018
[TBL] [Abstract][Full Text] [Related]
8. A multifunctional 5-aminolevulinic acid derivative induces erythroid differentiation of K562 human erythroleukemic cells.
Berkovitch-Luria G; Yakobovitch S; Weitman M; Nudelman A; Rozic G; Rephaeli A; Malik Z
Eur J Pharm Sci; 2012 Aug; 47(1):206-14. PubMed ID: 22705251
[TBL] [Abstract][Full Text] [Related]
9. Glycine and Folate Ameliorate Models of Congenital Sideroblastic Anemia.
Fernández-Murray JP; Prykhozhij SV; Dufay JN; Steele SL; Gaston D; Nasrallah GK; Coombs AJ; Liwski RS; Fernandez CV; Berman JN; McMaster CR
PLoS Genet; 2016 Jan; 12(1):e1005783. PubMed ID: 26821380
[TBL] [Abstract][Full Text] [Related]
10. Anti-Correlation between the Dynamics of the Active Site Loop and C-Terminal Tail in Relation to the Homodimer Asymmetry of the Mouse Erythroid 5-Aminolevulinate Synthase.
Na I; Catena D; Kong MJ; Ferreira GC; Uversky VN
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29958424
[TBL] [Abstract][Full Text] [Related]
11. A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia.
Bekri S; May A; Cotter PD; Al-Sabah AI; Guo X; Masters GS; Bishop DF
Blood; 2003 Jul; 102(2):698-704. PubMed ID: 12663458
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology and genetic mutations in congenital sideroblastic anemia.
Fujiwara T; Harigae H
Pediatr Int; 2013 Dec; 55(6):675-9. PubMed ID: 24003969
[TBL] [Abstract][Full Text] [Related]
13. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts.
Cotter PD; May A; Fitzsimons EJ; Houston T; Woodcock BE; al-Sabah AI; Wong L; Bishop DF
J Clin Invest; 1995 Oct; 96(4):2090-6. PubMed ID: 7560104
[TBL] [Abstract][Full Text] [Related]
14. Molecular defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia.
Bottomley SS; May BK; Cox TC; Cotter PD; Bishop DF
J Bioenerg Biomembr; 1995 Apr; 27(2):161-8. PubMed ID: 7592563
[TBL] [Abstract][Full Text] [Related]
15. New mutation in erythroid-specific delta-aminolevulinate synthase as the cause of X-linked sideroblastic anemia responsive to pyridoxine.
Kucerova J; Horvathova M; Mojzikova R; Belohlavkova P; Cermak J; Divoky V
Acta Haematol; 2011; 125(4):193-7. PubMed ID: 21252495
[TBL] [Abstract][Full Text] [Related]
16. X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the β-subunit of succinyl-CoA synthetase (SUCLA2).
Bishop DF; Tchaikovskii V; Hoffbrand AV; Fraser ME; Margolis S
J Biol Chem; 2012 Aug; 287(34):28943-55. PubMed ID: 22740690
[TBL] [Abstract][Full Text] [Related]
17. Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia.
Morimoto Y; Chonabayashi K; Kawabata H; Okubo C; Yamasaki-Morita M; Nishikawa M; Narita M; Inagaki A; Nakanishi K; Nagao M; Takaori-Kondo A; Yoshida Y
Blood Adv; 2022 Feb; 6(4):1100-1114. PubMed ID: 34781359
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for dysregulation of aminolevulinic acid synthase in human disease.
Taylor JL; Brown BL
J Biol Chem; 2022 Mar; 298(3):101643. PubMed ID: 35093382
[TBL] [Abstract][Full Text] [Related]
19. Regulation of heme metabolism in normal and sideroblastic bone marrow cells in culture.
Ibraham NG; Lutton JD; Hoffman R; Levere RD
J Lab Clin Med; 1985 May; 105(5):593-600. PubMed ID: 3989352
[TBL] [Abstract][Full Text] [Related]
20. The molecular basis of the sideroblastic anemias.
Fitzsimons EJ; May A
Curr Opin Hematol; 1996 Mar; 3(2):167-72. PubMed ID: 9372069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
